報價延遲最少15分鐘:2025/09/14 16:50 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.95 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.18/0.11
|
|
企業價值
835.02M
|
| 資產負債 |
|
每股賬面淨值
0.11
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
160.18M
|
|
每股收益
0.76
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/09/14 16:50 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development. |
